Video: Changing focus: Creating deal and business models with faster returns in mind
A few nimble VCs and entrepreneurs are developing funds and corporate structures that may once again make private biotech companies attractive investments. Companies changing the game have one common theme: they focus on the drug, not the company. Moderator Ruediger Herrmann, Partner at WilmerHale, and panelists explore these nascent deal and company structures as well as innovative approaches to rethinking the drug development model.
© 2012 EBD Group AG
Related Posts